

Supplementary Material 1 Summary of treatment-related local intolerances^a, treatment-related adverse events, and adverse events leading to discontinuation from Baseline to Day 25.

	Tyrosine 0.1% (n = 24)	Benzoylperoxide (BPO) 5% (n = 12)	Clindamycin + BPO (n = 12)
<i>Local Intolerances</i>			
Scaling mild	10 (41.7%)	11 (91.7%)	6 (50%)
Scaling moderate	0	3 (25%)	1 (8.3%)
Scaling severe	0	1 (8.3%)	0
Erythema mild	8 (33.3%)	6 (50%)	3 (25%)
Erythema moderate	1 (4.2%)	7 (58.3%)	0
Erythema severe	0	0	1 (8.3%)
Itching mild	6 (25%)	2 (16.7%)	3 (25%)
Itching moderate	1 (4.2%)	0	0
Itching severe	0	0	1 (8.3%)
Burning mild	2 (8.3%)	2 (16.7%)	1 (8.3%)
Burning moderate	0	0	1 (8.3%)
Stinging mild	1 (4.2%)	1 (8.3%)	1 (8.3%)
<i>Adverse events</i>			
Edema mild	0	1 (8.3%)	0
Edema moderate	2 (8.3%)	1 (8.3%)	0
Facial dryness mild	0	1 (8.3%)	0
Facial tension mild	0	0	1 (8.3%)
Painfully tense feeling mild	0	1 (8.3%)	0
<i>Adverse events leading to discontinuation</i>			
Edema moderate (intolerance reaction)	0	0	1 (8.3%)
<i>Total related adverse events^b (n)</i>	31	37	20

^a Local intolerances were classified as scaling, erythema assessed by the investigator and itching, burning, stinging by self-assessment of the patient. Intensities were scored as none=0, mild=1, moderate=2, severe=3.

^b Local Intolerances included.